Simultaneous Multinuclear Magnetic Resonance Fingerprinting for Data Fusion of Quantitative Structural and Metabolic Imaging
This proposal seeks to perform an observational study, for evaluating a new non-invasive imaging technique that will provide multi-parametric metabolic 3D maps of the living brain at an unprecedented resolution, based on the fusion of simultaneously acquired proton and sodium MRI data. The new fused high-resolution structural and metabolic maps will provide new insights into neuro-architecture, neuro-biochemistry and their interconnection, which are crucial for our understanding of the human brain and its disorders. It will be tested for management of patients with chronic steno-occlusive disease and/or with recurrent transient ischemic attacks (TIA)/minor stroke).
Single-center observational longitudinal study to identify predictors of progression of joint damage after non-contact rupture of anterior cruciate ligament
Post-traumatic osteoarthritis (PTOA) is a common occurrence after anterior cruciate ligament (ACL) rupture independently of patient treatment, which indicates that early cellular and molecular changes directly after injury seem to be critical in disease development. The goal of this study is to develop a predictive model of progressionto PTOA using a combination of multinuclear magnetic resonance imaging markers, soluble synovial fluid biological markers, and biomechanical markers acquired on patients just after ACL injury, and at different time points after joint repair. This prognostic combination of biomarkers will help identify therapeutic targets and monitor theefficacy of intervention in the development of preventive treatments of PTOA.
Single-Center Pilot Study of Living Donor Kidney Transplant from HIV-positive Donor to HIV-positive Recipient
This study will evaluate the feasibility and safety of living donor kidney transplant from an HIV-infected donor to an HIV-infected recipient.
Single-center study of fiber tractography in brain tumor surgery
The value of DWI fiber tractography for a neurosurgeon depends on its ability to trace fiber bundles from the brain stem all the way to the relevant cortical areas regardless of peritumoral edema, displacement and mass effect caused by lesions. We will perform MRI scans of healthy volunteers (30 volunteers, 2 hours scan time) and brain tumor patients (25 volunteers, 1 hour scan time in addition to the clinically indicated MRI scan) and evaluate the quality of conventional and ODF-Fingerprinting fiber tracts to assess the value of the novel ODF-Fingerprinting method in brain surgery.
Sinonasal Cancer | NYU Langone Health
Doctors at Perlmutter Cancer Center manage sinonasal cancer with surgery, radiation therapy, and chemotherapy.
Sinonasal Disorder Services for Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone create child-centered care plans to manage disorders affecting the nose and sinus.
Site for A Longitudinal Prospective Observational Study of the Characteristics Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States
Site for A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States
Site for A Multicenter Randomized Double-Blind Parallel Group Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure
Site for This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (LVEF =40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
Site for A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Non-Biologic Lupus Standard of Care
Site for This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study designed to evaluate the efficacy and safety of BIIB059 in participants = 18 years of age with active SLE, including joint and/or skin manifestations, who are receiving background nonbiologic lupus SOC therapy. The study will be conducted at approximately 135 sites globally. Approximately 540 participants will be randomized 1:1:1 to receive BIIB059 450 mg, BIIB059 225 mg, or placebo SC Q4W, with an additional dose at Week 2, as add-on to background nonbiologic lupusSOC therapy.The study includes a screening period of up to 4 weeks; a double-blind, placebo-controlled treatment period of 52 weeks; and an SFU period (off-treatment) of 24 weeks. Details of these different study periods are given below.
Site for A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Na ve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
Site for A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer